Table III.
Survival outcomes.
| Author, year | LC rate,% | PSF rate, % | Median PFS time, months | OS rate, % | Median OS time, months | Toxicity criteria | Acute toxicity, grade ≥3, % (n) | Late toxicity, grade ≥3, % (n) | Tumour response, % | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|
| Shen et al, 2017 | NR | 1-year: 50.0 2-year: 21.4 | 11.0 | 1-year: 57.1 2-year: 32.1 | 15.0 | CTCAE v.4.0 | Nausea: 3.6(1) Anorexia: 7.1(2) Vomiting: 3.6(1) Gastric ulcer: 3.6(1) Altered hepatic values: 25.0(7) Haematological toxicity: 10.8(3) | NR | Complete response: 10.7 Partial response: 35.7 Stable disease: 42.9 Progressive disease: 10.7 (RECIST criteria) | (15) |
| Weiner et al, 2016 | NRS | 1-year: 68.0 | 24.7 | 1-year: 51.0 | 13.2 | CTCAE v.4.0 | 65.4(17)a | 69.2(18)a | Radiographic response: 33.3 Complete radiographic response: 8.3 (EASL criteria) | (16) |
| Klein et al, 2015 | NR | NR | NR | NR | 12.1 | NR | NR | NR | NR | (17) |
| Jung et al, 2014 | 1-year: 85.0 2-year: 71.0 | NR | NR | 1-year: 39.0 2-year: 18.0 | 10.0 | CTCAE v.4.0 | 3.4(2)a | 6.9(4)a | NR | (18) |
| Sebastian et al, 2019 | NR | NR | NR | NR | 48.0 | NR | NR | NR | NR | (19) |
| Kozak et al, 2020 | Local failures: 40.0 Regional failures: 8.0 | NR | NR | NR | 23.0 | NR | Hepatobiliary: 42.5(17)a Non-hepatobiliary: 2.5(1)a | Hepatobiliary: 42.5(17)a Non-hepatobiliary: 2.5(1)a | NR | (20) |
aData including other sites of biliary cancers. CTCAE, Common Terminology Criteria for Adverse Events (32); EASL, European Association for the Study of the Liver (33); LC, local control; NR, not reported; NRS, not reported separately; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria In Solid Tumours (34).